Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression
Khouri IF, Wei W, Valverde R, et al.
Key Points:
Safety and efficacy of BFR as non-myeloablative conditioning regimen in patients with lymphoid malignancies investigated
Regimen well-tolerated with 1-year treatment-related mortality of 9%
Engraftment occurred with minimal myelosuppression
Implications:
- BFM may represent novel conditioning regimen for allogeneic transplantation in outpatient setting
View the original abstract on the ASH website.
